Characterization of Replication-Competent Adenovirus Isolates from Large-Scale Production of a Recombinant Adenoviral Vector
- 1 January 1999
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 10 (1) , 113-121
- https://doi.org/10.1089/10430349950019246
Abstract
Replication-deficient adenoviral vectors have been developed for the delivery of DNA sequences encoding a variety of proteins intended for the management of disease through gene therapy. One concern is the occur- rence of replication-competent adenovirus (RCA) in the population of replication-deficient adenoviral vectors as a result of recombination or contamination. To address this concern, it is necessary to determine the fre- quency of occurrence and to fully characterize the molecular structure and biological infectivity of RCA. rAd/p53 is a pIX-deleted p53 gene therapy vector that is designed to lower the RCA occurrence and to de- liver the tumor suppresser gene p53 for treatment of various cancers. Multiple preparations of the replica- tion-deficient adenoviral vector rAd/p53 were tested for the presence of RCA, employing a sensitive biologi- cal assay. Single plaques from RCA-positive preparations of rAd/p53 were isolated for molecular characterization. All of the RCA isolates displayed a single unique structure that contains the complete E1 sequence of adenovirus type 5 but lacks the p53 sequence. The detailed sequence analysis of the RCA sug- gests that it is most likely generated as a result of recombination events between the rAd/p53 DNA and the 293 host adenoviral sequence. Results from viral infectivity analysis by flow cytometry demonstrate no sub- stantial difference in infectivity of RCA, rAd/p53, and wild-type adenovirus type 5 in 293 cells.Keywords
This publication has 29 references indexed in Scilit:
- Analytical Anion-Exchange HPLC of Recombinant Type-5 Adenoviral ParticlesHuman Gene Therapy, 1997
- Gene therapy for lung cancer: Enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transferThe Journal of Thoracic and Cardiovascular Surgery, 1996
- Purification of a Type 5 Recombinant Adenovirus Encoding Human p53 by Column ChromatographyHuman Gene Therapy, 1995
- Gene therapy using adenoviral vectorsCurrent Opinion in Biotechnology, 1994
- Emergence of Early Region 1-Containing Replication-Competent Adenovirus in Stocks of Replication-Defective Adenovirus Recombinants (ΔE1 + ΔE3) During Multiple Passages in 293 CellsHuman Gene Therapy, 1994
- Development and Analysis of Recombinant Adenoviruses for Gene Therapy of Cystic FibrosisHuman Gene Therapy, 1993
- Eight ‘Musts’ for BiotechnologyNature Biotechnology, 1988
- Adenovirus VAI RNA is required for efficient translation of viral mRNAs at late times after infectionCell, 1982
- The structure of replicating adenovirus 2 DNA moleculesCell, 1977
- Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5Journal of General Virology, 1977